Company profile
Petros Pharmaceuticals, Inc. CIK 1815903
Ticker
PTPI (OTC)
Industry
Pharmaceutical Preparations
Headquarters
New York, NY 10036
Fiscal year end
2025 (FY)
Key Financials
Revenue
—
Net income
$1.91M
Total assets
$5.16M
Total liabilities
$2.29M
Stockholders' equity
$2.87M
Cash & equivalents
$5.14M
Operating income
-$4.64M
Operating cash flow
-$6.73M
Capital expenditures
—
Fiscal year 2025, via 10-K filed 2026-04-15. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
44.4%
Equity / assets
55.6%
CapEx / revenue
—
Operating cash flow / net income
-3.52×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025
—
$1.91M
$5.16M
$2.29M
$2.87M
2024
$5.11M
-$14.32M
$10.64M
$18.10M
-$7.47M
2023
$5.82M
-$8.16M
$33.80M
$21.32M
$12.07M
2022
$5.99M
-$20.04M
$32.42M
$15.72M
$16.70M
2021
$7.81M
-$8.99M
$67.39M
$31.85M
$35.54M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 10-Q
2026-08-13
Financials filed via
Form 10-K
filed 2026-04-15
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
New York, NY 10036
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:45 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.